September 1, 2022Journal of Cardiovascular Pharmacology
Autoantibodies and Cardiomyopathy: Focus on Beta-1 Adrenergic Receptor Autoantibodies
Key result
Beta-1 adrenergic receptor autoantibodies exhibit diverse pharmacological properties and signaling responses that play a determinant role in the progression and outcomes of dilated cardiomyopathy.
Why the study?
The molecular basis of the modulatory effects of β1AR autoantibodies and their diverse roles in mediating dilated cardiomyopathy outcomes remain poorly understood.
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Challenges view of uniformly deleterious beta-1 AR autoantibodies in DCM; extends understanding but leaves therapeutic targeting open for trials.
Structured PICO
P
Population
Patients with dilated cardiomyopathy (DCM) and cellular/animal models
This review emphasizes the complex and diverse roles of beta-1 adrenergic receptor autoantibodies in dilated cardiomyopathy, suggesting that specific subclasses may offer beneficial rather than purely deleterious effects.
Cite This Study
Tang et al. (2022) conducted a review in Dilated cardiomyopathy (DCM). Beta-1 adrenergic receptor (β1AR) autoantibodies was evaluated. Beta-1 adrenergic receptor autoantibodies exhibit diverse pharmacological properties and signaling responses that play a determinant role in the progression and outcomes of dilated cardiomyopathy.